• US Trials
• European Trials
• Other Trials

Title	# of Patients	Sites	Objective	Status
ANGEL Phase I Trial	5 Patients	Hospital Angeles	Phase I study to assess safety and feasibility of LipiCell™	Currenlty enrolling
MARVEL (Phase II/III Clinical Trial)	MARVEL Part 1: 20 Patients (completed) MARVEL Part 2: 133 Patients	Up to 35 sites in the United States	Designed to be a double blind, randomized, placebo controlled multi-center trial to evaluate the safety and efficacy of MyoCell® delivered via MyoStar®	MyoCell® implantation procedure completed on first patient in October 2007. MARVEL part 1 data on the first 20 patients analyzed and presented at the Heart Failure Society of America (HFSA) Meeting in 2009. Data displayed overall positive clinical result
MYOHEART (Phase I Clinical Trial)	20	Five sites in the United States	Trials have been designed to test the safety and efficacy of MyoCell in treating patients with severe, chronic damage to the heart.	Trial commenced in 2003; treatment of all 20 patients completed in October 2006; final twelve-month data presented in January 2008.
REGEN (Phase I Clinical Trial)	15	3 Sites in US	Designed to test the safety and effectiveness of a composition of muscle stem cells that have been gene-modified to induce a greater than usual release of the SDF-1 protein	Approval received in July 2009 from the FDA to move forward with the trail.

Title	# of Patients	Sites	Objective	Status
2002 Trial	3	One site in the Netherlands		Trial commenced in 2002. Discontinued upon Transvascular's acquisition by Medtronic.
Netherlands Phase I Clinical Trial	5	One site in the Netherlands	Pilot study to assess safety and feasibility of MyoCell®.	Trail commenced in 2001; six-month follow-up completed in October 2003.
Phase I/II Clinical Trial	15	Three sites in the Netherlands, Germany and Italy.		Trial commenced in 2002; twelve-month follow-up completed in June 2004.
SEISMIC (Phase II Clinical Trial)	40, including 14 controls.	Twelve sites in the Netherlands, Germany, Belgium, Spain, Poland, and the United Kingdom.	Phase II European study to assess the safety and efficacy of MyoCell® therapy delivered via MyoCath® catheter.	Trail commenced in November 2005; treatment of all patients completed in July 2007; final results presented in April 2008.

Title	# of Patients	Sites	Objective	Status
Centers of Excellence		Sites in Korea, Mexico, Switzerland.	Phase I and II	Requisite regulatory approval to conduct trials received at all sites